Atrasentan Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Atrasentan Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
27
Registered trials
42
Result records
5
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Atrasentan Hydrochloride can convert its Small molecule drug profile and ETA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Atrasentan Hydrochloride (query alias: atrasentan) |
|---|---|
| Modality / target | Small molecule drug; ETA; ETA antagonists |
| Highest global status | Approved |
| Originator | Novartis Pharmaceuticals Corp. |
| Active developers | AbbVie Ireland NL B.V., Chinook Therapeutics U.S., Inc., Novartis Pharma AG |
The MCP disease footprint includes Glomerulonephritis, IGA, Glomerular disease, Glomerulosclerosis, Focal Segmental. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07498335 | Phase 3 | Recruiting | 28 | Change From Baseline in Proteinuria at Week 36 |
| NCT05834738 | Phase 2 | Completed | 54 | Change From Baseline in Proteinuria at Week 12 in Both Treatment Periods 1 and 2 |
| NCT06952426 | Not Applicable | Recruiting | 300 | Number of participants with IgAN specific symptoms |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
New Era for FSGS Treatment
Not Applicable; n=620; evaluation: Positive. Reported fields: Optimally managed = Nephrologists rank FSGS among the top three rare kidney diseases with sizable unmet therapeutic needs. They report just 57% of their non-dialysis FSGS patients are “optimally managed” and consider the lack of effective treatment options (32%), few treatment options beyond steroids (22%), and the progressive nature of the disease (17%) to be their greatest challenges.
Efficacy and Safety of Atrasentan in Patients (Pts) with IgAN from East (E) Asia: Phase 3 ALIGN Interim Data
Phase 3; n=120; evaluation: Positive. Reported fields: TEAE(discontinuation) = 3.3 % ; TEAE(discontinuation) = 3.4 %
#3015 ALIGN post-hoc analyses: Reduction in proteinuria with atrasentan across subgroups by MEST-C score, baseline hematuria and baseline UPCR
Phase 3; n=270; evaluation: Positive. Reported fields: UPCR(36-week): Reduction = 36.1(95.0% CI, 26.4 - 44.6), P-Value = < 0.0001; UPCR(36-week): Reduction = 36.1(95.0% CI, 26.4 - 44.6), P-Value = < 0.0001
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Atrasentan Hydrochloride addresses Glomerulonephritis, IGA, Glomerular disease, Glomerulosclerosis, Focal Segmental. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-04-07 | CareMed Has Been Selected as a National Specialty Pharmacy Partner for VANRAFIA™ (atrasentan) | Approved | Financial terms not disclosed |
| 2023-07-28 | 信瑞诺医药与合全药业达成战略合作 | Phase 3 | Financial terms not disclosed |
| 2023-06-12 | Novartis Completes Acquisition of Chinook Therapeutics | Phase 3 | US$3,200.0M upfront; US$300.0M milestones; US$3,500.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “LC-ms/ms method for the quantification of atrasentan in human plasma”. The milestone feed surfaced a patent-application signal described as “Methods of treating focal segmental glomerulosclerosis with atrasentan”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
